Rossari Biotech FY26 Annual Report: Revenue Rs 23,964 mn, up 15%

ROSSARI · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-1.2%1-day move

₹531.25

prior close

₹530.10

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-0.9-1.2-1.1-0.3-1.2-1.3-1.7-1.6+0.3-4.8-2.7———

Up moveDown movePending

AI summary

Rossari Biotech filed its Integrated Annual Report for FY2025-26. Revenue rose 15.19% to Rs 23,963.65 million. EBITDA stood at Rs 2,859.03 million and PAT at Rs 1,492.13 million. Exports grew 11% to Rs 6,343.01 million, contributing 26% of turnover across 80+ countries. Company invested Rs 2,445 million in capex, commissioning new ethoxylation capacity at Dahej taking total to 66,000 MTPA. ROCE at 14.81%, ROE at 11.85%. Board recommends final dividend of Rs 0.50 per share. 17th AGM on July 20, 2026.

Likely market impact

Steady growth with stable margins, new capacity ramping up, and expansion into pharma, oil & gas, and biosurfactants for next phase of earnings.